Next Phase Newsletter

A Canada-based private social venture capital firm invests in early-stage companies, and is currently interested in new developments in the healthtech and biotech sectors. The firm is open to exploring a wide range of opportunities. The founder of the firm is an accomplished investor of 20+ years with a track record of scaling successful businesses, mostly in the technology sectors. The founder has also established a foundation to support the growth and activities of organizations dedicated to developing innovative, system-changing solutions with high potential for global impact. With both initiatives, the founder has been actively working with like-minded companies and funds in Canada.

The firm’s initial investments are generally in the $100-500K range with a few exceptions. Their geographical focus lies in North America and all investments have been based in USA and Canada, but the firm is open to considering global opportunities.

The firm has broad interests in life sciences and is open to considering all early-stage opportunities in therapeutics, medical devices, diagnostics, and healthcare IT. The firm is particularly interested in preventative/proactive technologies that can significantly benefit health management.

The firm does not have specific management team requirements but prefers to see teams with a successful track record and relevant expertise. The firm generally does not lead investment rounds or seek board representation.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global venture capital firm founded in 1995 has offices in the Silicon Valley area and China. The firm recently closed a $750 million fund as well as a smaller $150 million fund. The firm invests exclusively in the life science sector and invests primarily in the USA and China, but will also invest in other regions such as Europe and Canada. Within China, the firm makes growth investments in companies that have existing revenues; in the USA and other regions, the firm makes both venture and growth-equity stage investments in both pre-revenue and revenue-stage companies. The firm’s allocations are highly varied. From the main fund, investments typically range from $10-30m, though larger investments are of interest as well; the firm’s smaller fund makes investments of typically $2-5 million, generally in financing rounds of $10 million or less. The firm is open to syndication. The firm is also particularly interested in working with companies that are open to or actively interested in seeking partnerships or opportunities in China.

The firm invests in therapeutics, medical devices, diagnostics, healthcare services, and clinically-oriented healthcare IT, and will consider investing in any indication area or technology subsector; however, orphan indications, dermatology/aesthetics, oncology, and blood diseases are of particular interest in the biopharma space; general surgery, neurovascular, cardiovascular, minimally invasive technologies, women’s health, respiratory care, novel diagnostics and orthopedics are of particular interest in the device space. The smaller fund focuses on early stage opportunities in biotech; from the main fund, the firm in most cases makes investments in products that have obtained market approval or are very close to commercialization, but earlier investments may be considered for highly innovative products or products that can demonstrate strong efficacy signals at an earlier stage (such as anti-infectives). For devices and diagnostics, the firm only invests in commercial-stage companies. Generally, the firm does not invest in imaging.

The firm is flexible regarding management teams, and works with both serial entrepreneurs and entrepreneurs who lack industry experience. In addition to investing in private companies, The firm is able to invest in public companies by means of PIPEs or public market placements. The firm is interested in investing in companies with products that can demonstrate cost-effectiveness.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate investment group invests strategically on behalf of a large medical technology corporate. The firm uses a variety of structures to work with early stage medical technology companies, including both licensing relationships and equity investments on a case by case basis. The firm is a flexible investor, and the firm’s allocation sizes are wide ranging. The firm invests worldwide.

The firm invests in sectors that are relevant to the corporate’s business groups – areas of interests include cardiovascular, diabetes, restorative therapies, and minimally invasive therapies. This includes interests in spinal implants, neuromodulation treatments for pain and urological disorders, deep brain stimulation, neurovascular devices, general surgery, gastrointestinal care, pulmonology, respiratory care and monitoring technologies, etc. The firm is interested in diversifying the corporate’s product and services offerings within all of these areas of interests and also in integrating new fields of information technology and services into the strategic areas, such as IT-enabled patient monitoring and contract management of provider facilities. The firm invests at a range of development stages but generally prefers to work with companies that have obtained clinical data regarding their asset.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Canada-based investment firm that was founded in 2000 has two Health Tech Venture funds that invested in a total of 26 companies, mostly in Canada. The firm is currently in the process of raising its third fund. The firm invests in the health technology sector, especially medical technology and digital health. The second fund focuses on pre and post Series A investments with the ability to do follow-on funding. The investment size can range from $100K to over $1M and up to $2-4M with follow-on funding. The capital structure is flexible, especially as they are currently raising their third fund. The firm typically co-invests and will lead investments depending on the occasion and size of the round. Investment can be in form of equity, whereas convertible loan and other capital structures will be considered. The new fund looks to invest in 10-20 companies. The firm focuses on companies based in Canada, but it will also look at opportunities in the US. The firm’s investment activity has catalyzed over $200M of investment in the Canadian venture capital space.

In the life sciences, the firm is currently looking for new investments in the medical technology, diagnostics, digital health, AI applications in healthcare, surgical robotics and healthcare IT sectors with a particular interest in medical devices with a software component. The firm is interested in all classes of medical devices and is indication agnostic. The firm is focused on preclinical to clinical stage technology and is focused on technology that requires an FDA regulatory pathway. The firm will consider therapeutics companies from time-to-time, however, therapeutics is not the firm’s focus. Historically, the firm was active in a company developing blood-testing platform for infectious diseases.

The firm focuses on investments in private companies with an experienced management team and growth potential. The firm will take a board seat based on case-by-case basis, though is not the requirement.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Vancouver-based venture capital firm actively invests in health technology, sports technology, fitness, and nutrition businesses. The firm is an early-stage investor and focuses on investing in Seed to Series A rounds. The firm makes initial investments up to $100K through equity or convertible notes and will make 2-4 investments per year. The firm is raising a new fund that will focus on companies along the Pacific Coast of the USA and across Canada, but currently focuses on investing in Canada-based companies. With the launch of the new venture fund, the firm will invest up to $500k in first rounds.

The firm is dedicated to investing in preventative health and proactive technology solutions that optimize health, activity and longevity. As social impact and technology investors, the firm is committed to the development of technologies, products and services that both enhance and promote an individual’s ability to stay optimally healthy and active over an entire lifetime.

The firm focuses on innovative health technologies including digital health, mobile health, sport technology, wearable technology, and those that help with chronic disease management and corporate wellness initiatives. The firm is very interested in consumer-facing technologies that can enhance health and wellness, quality of care, as well as technologies that could be used in developing preventative health strategies and solutions. The firm does not have minimum revenue requirements and will consider companies in their earliest stages as long as they demonstrate high growth potential. The firm will not consider therapeutics or diagnostic companies. Medical devices subject to a 510k approval process will be considered.

The firm seeks to invest in private companies developing technologies that positively impact health and wellness. The firm can work with all types of management teams with flexibility, although strong experience and a successful track record is a plus. The firm works closely with their portfolio companies and will provide needed expertise, including access to an international network of strategic advisors to support their growth.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A cross-border venture capital group based out of Toronto, Ontario is currently expanding into the healthcare space. The firm is currently seeking to make 1-2 investments within the healthcare space in the next 2 quarters. The firm prefers early stage investments from seed extension to series B, but can go up to series C. The firm can move quicker on small investments but slower for larger sized investments if syndication with Chinese investors is required. The firm does not typically lead investments and will consider opportunities within the US and Canada. The firm focuses on companies that have a strong China angle as they can provide help with entry into the Chinese market, with soft landings via their resources in China. The firm is particularly interested in platform technologies with strong, protectable IP with a high difficulty to replicate.

The firm is looking for opportunities within the medical device and digital health space. The firm prefers platform technologies that are applicable across multiple indications. The firm is opportunistic and has no preference towards indication. The firm has recently invested in an analytical device company that seeks to help research labs develop new therapeutics. For digital health companies, the firm prefers technologies that are applicable and deployable in China, while not easily duplicated. The firm prefers to invest in companies with some commercialization or are close to commercialization, but at minimal with market validation.

The firm prefers management teams with a strong scientific background and has an interest in expanding into China. The firm prefers to take a board seat in companies that currently lack a China expert so they can help the company with their expertise in working in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A large real-estate company based in Canada looking to expand their investments into the healthcare field. The firm is looking to invest $4-5 million into various startups in the upcoming year, seeking opportunities at the Seed to Series A range. The firm is willing to both lead and follow on investments they make and are looking for opportunities solely within the US and Canada.

The firm is looking for opportunities within the Medical Device, Digital Health, Diagnostics, and Biotech R&D Spaces. Specifically, the firm is looking for technologies that can help physicians. Examples of such technologies include: telemedicine, clinical trial services for physicians, and digital health solutions to help patient engagement. The firm is also interested in new medical devices and diagnostic technologies that are in the clinical trial stage.

The firm is looking for a strong management team who has a strong vision and development plan for the technology of interest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.